阿尔茨海默病视觉障碍研究进展

doi:10.3969/j.issn.1006-9771.2020.01.012

摘要/Abstract

摘要：

近年来发现,阿尔茨海默病(AD)患者视网膜中也存在β-淀粉样蛋白沉积,与颅内改变同步。AD患者存在视敏度和视觉对比敏感度受损、青光眼样视野改变、色觉障碍、视幻觉、视空间受损等功能损害;视网膜厚度变薄,视网膜电图潜伏期延长和振幅减低,视觉诱发电位潜伏期延长。

关键词: 阿尔茨海默病, 视网膜, 视觉, 综述

Abstract:

In recent years, it is found that β-amyloid deposites in the retina of patients with Alzheimer's disease (AD), synchronizing with intracranial changes. AD patients lose their visual acuity and visual contrast sensitivity and demonstrate glaucoma-like visual field loss, color vision disorder, visual hallucination and visual space damage, etc. The retinas become thinner, the latency of electroretinogram prolongs with amplitude decrease, and the latency of visual-evoked potential prolongs.

Key words: Alzheimer's disease, retina, vision, review

中图分类号:

R749.1

张静,李晓红,刘丽军. 阿尔茨海默病视觉障碍研究进展[J]. 《中国康复理论与实践》, 2020, 26(1): 67-69.

ZHANG Jing,LI Xiao-hong,LIU Li-jun. Advance in Visual Dysfunction for Alzheimer's Disease (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2020, 26(1): 67-69.

参考文献 34

[1]	Koronyo-Hamaoui M, Koronyo Y, Ljubimov A V, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model[J]. Neuroimage, 2011, 54(Suppl 1):S204-S217. doi: 10.1016/j.neuroimage.2010.06.020
[2]	Ho C Y, Troncoso J C, Knox D, et al. β-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients[J]. Brain Pathol, 2014, 24(1):25-32. doi: 10.1111/bpa.2014.24.issue-1
[3]	Schon C, Hoffmann N A, Ochs S M, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice[J]. PLoS One, 2012, 7(12):e53547. doi: 10.1371/journal.pone.0053547
[4]	More S S, Beach J M, Vince R. Early detection of amyloidopathy in Alzheimer's mice by hyperspectral endoscopy[J]. Invest Ophthalmol Vis Sci, 2016, 57(7):3231-3238. doi: 10.1167/iovs.15-17406
[5]	Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease[J]. JCI Insight, 2017, 2(16):93621.
[6]	Uhlmann R F, Larson E B, Koepsell T D, et al. Visual impairment and cognitive dysfunction in Alzheimer's disease[J]. J Gen Intern Med, 1991, 6(2):126-132. pmid: 2023019
[7]	Spierer O, Fischer N, Barak A, et al. Correlation between vision and cognitive function in the elderly: a cross-sectional study[J]. Medicine (Baltimore), 2016, 95(3):e2423. doi: 10.1097/MD.0000000000002423
[8]	Chriqui E, Kergoat M J, Champoux N, et al. Visual acuity in institutionalized seniors with moderate to severe dementia[J]. J Am Med Dir Assoc, 2013, 14(4):275-279. doi: 10.1016/j.jamda.2012.11.005
[9]	Ciocler Froiman P, Dantas P E. Assessment of visual acuity in patients with dementia using teller acuity cards[J]. Strabismus, 2013, 21(2):93-97. doi: 10.3109/09273972.2013.787634
[10]	Polo V, Rodrigo M J, Garcia-Martin E, et al. Visual dysfunction and its correlation with retinal changes in patients with Alzheimer's disease[J]. Eye (Lond), 2017, 31(7):1034-1041. doi: 10.1038/eye.2017.23 pmid: 28282060
[11]	Risacher S L, Wudunn D, Pepin S M, et al. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints[J]. Neurobiol Aging, 2013, 34(4):1133-1144. doi: 10.1016/j.neurobiolaging.2012.08.007 pmid: 23084085
[12]	Bayer Andreas U, Keller Othmar N, Ferrari F, et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease[J]. Am J Ophthalmol, 2002, 133(1):135-137. pmid: 11755850
[13]	Cesareo M, Martucci A, Ciuffoletti E, et al. Association between Alzheimer's disease and glaucoma: a study based on Heidelberg retinal tomography and frequency doubling technology perimetry[J]. Front Neurosci, 2015, 9:479.
[14]	Sugiyama T, Utsunomiya K, Ota H, et al. Comparative study of cerebral blood flow in patients with normal-tension glaucoma and control subjects[J]. Am J Ophthalmol, 2006, 141(2):394-396. pmid: 16458708
[15]	Salobrar-Garcia E, de Hoz R, Rojas B, et al. Ophthalmologic psychophysical tests support OCT findings in mild Alzheimer's disease[J]. J Ophthalmol, 2015, 2015:736949. doi: 10.1155/2015/736949 pmid: 26106485
[16]	Salamone G, Di Lorenzo C, Mosti S, et al. Color discrimination performance in patients with Alzheimer's disease[J]. Dement Geriatr Cogn Disord, 2009, 27(6):501-507. doi: 10.1159/000218366
[17]	Arnaoutoglou N A, Arnaoutoglou M, Nemtsas P, et al. Color perception differentiates Alzheimer's disease (AD) from vascular dementia (VaD) patients[J]. Int Psychogeriatr, 2017, 29(8):1355-1361. doi: 10.1017/S1041610217000096 pmid: 28325166
[18]	Chiu P Y, Hsu M H, Wang C W, et al. Visual hallucinations in Alzheimer's disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies[J]. PLoS One, 2017, 12(10):e0186886. doi: 10.1371/journal.pone.0186886
[19]	Lin S H, Yu C Y, Pai M C. The occipital white matter lesions in Alzheimer's disease patients with visual hallucinations[J]. Clin Imaging, 2006, 30(6):388-393. doi: 10.1016/j.clinimag.2006.09.025
[20]	El Haj M, Larøi F, Gely-Nargeot M C, et al. Inhibitory deterioration may contribute to hallucinations in Alzheimer's disease[J]. Cogn Neuropsychiatry, 2015, 20(4):281-295. doi: 10.1080/13546805.2015.1023392
[21]	Suárez-González A, Serrano-Pozo A, Arroyo-Anlló E M, et al. Utility of neuropsychiatric tools in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease: quantitative and qualitative findings[J]. Int Psychogeriatr, 2014, 26(3):453-461. doi: 10.1017/S1041610213002068 pmid: 24284139
[22]	Hort J, Laczò J, Vyhnàlek M, et al. Spatial navigation deficit in amnestic mild cognitive impairment[J]. Proc Natl Acad Sci USA, 2007, 104(10):4042-4047. doi: 10.1073/pnas.0611314104
[23]	Alescio-Lautier B, Michel B F, Herrera C, et al. Visual and visuospatial short-term memory in mild cognitive impairment and Alzheimer disease: role of attention[J]. Neuropsychologia, 2007, 45(8):1948-1960. pmid: 17275041
[24]	Salimi S, Irish M, Foxe D, et al. Can visuospatial measures improve the diagnosis of Alzheimer's disease?[J]. Alzheimers Dement (Amst), 2018, 10:66-74.
[25]	Cunha J P, Proenca R, Dias-Santos A, et al. OCT in Alzheimer's disease: thinning of the RNFL and superior hemiretina[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(9):1827-1835. doi: 10.1007/s00417-017-3715-9
[26]	Santos C Y, Johnson L N, Sinoff S E, et al. Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease[J]. Alzheimers Dement (Amst), 2018, 10:196-209.
[27]	Polo V, Garcia-Martin E, Bambo M P, et al. Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer's disease[J]. Eye (Lond), 2014, 28(6):680-690. doi: 10.1038/eye.2014.51 pmid: 24625377
[28]	Valenti D A. Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease[J]. Int J Alzheimers Dis, 2011, 2010:793931. doi: 10.4061/2010/793931 pmid: 21253485
[29]	Larrosa J M, Garcia-Martin E, Bambo M P, et al. Potential new diagnostic tool for Alzheimer's disease using a linear discriminant function for Fourier domain optical coherence tomography[J]. Invest Ophthalmol Vis Sci, 2014, 55(5):3043-3051. doi: 10.1167/iovs.13-13629
[30]	Kergoat H, Kergoat M J, Justino L, et al. Visual retinocortical function in dementia of the Alzheimer type[J]. Gerontology, 2002, 48(4):197-203. pmid: 12053107
[31]	Krasodomska K, Lubiński W, Potemkowski A, et al. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease[J]. Doc Ophthalmol, 2010, 121(2):111-121. doi: 10.1007/s10633-010-9238-x pmid: 20549299
[32]	Parthasarathy R, Chow K M, Derafshi Z, et al. Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin[J]. Exp Eye Res, 2015, 138:134-144. doi: 10.1016/j.exer.2015.06.027 pmid: 26142956
[33]	Antes R, Ezra-Elia R, Weinberger D, et al. ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 mice[J]. PLoS One, 2013, 8(5):e64949. doi: 10.1371/journal.pone.0064949
[34]	Yamasaki T, Horie S, Ohyagi Y, et al. A potential VEP biomarker for mild cognitive impairment: evidence from selective visual deficitof higher-level dorsal pathway[J]. Alzheimers Dis, 2016, 53(2):661-676.